Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma

被引：56

作者：

Waldmann, T. A. ^{[1
]}

机构：

[1] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

ONCOGENE | 2007年 / 26卷 / 25期

关键词：

IL-2; receptor; adult T-cell leukemia; anti-Tac; monoclonal antibody;

D O I：

10.1038/sj.onc.1210368

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Daclizumab (Zenapax) identifies the alpha subunit of the interleukin-2 (IL-2) receptor and blocks the interaction of this cytokine with its growth factor receptor. The scientific basis for the choice of the IL-2 receptor alpha subunit as a target for monoclonal antibody-mediated therapy of leukemia/lymphoma is that very few normal cells express IL-2R alpha, whereas the abnormal T cells in patients with an array of lymphoid malignancies express this receptor. In 1997, daclizumab was approved by the FDA for use in the prevention of renal allograft rejection. In addition, anti-Tac provided effective therapy for select patients with T-cell malignancies and an array of inflammatory autoimmune disorders. Finally, therapy with this antibody armed with Y-90 has led to clinical responses in the majority of patients with adult T-cell leukemia. These insights concerning the IL-2/IL-2 receptor system facilitated the development of effective daclizumab antibody therapy for select patients with leukemia/lymphoma.

引用

页码：3699 / 3703

页数：5

共 42 条

[1] Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. [J].

Beniaminovitz, A ;

Itescu, S ;

Lietz, K ;

Donovan, M ;

Burke, EM ;

Groff, BD ;

Edwards, N ;

Mancini, DM .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (09) :613-619

[2] Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis [J].

Bielekova, B ;

Catalfamo, M ;

Reichert-Scrivner, S ;

Packer, A ;

Cerna, M ;

Waldmann, TA ;

McFarland, H ;

Henkart, PA ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5941-5946

[3] Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β [J].

Bielekova, B ;

Richert, N ;

Howard, T ;

Blevins, G ;

Markovic-Plese, S ;

McCartin, J ;

Würfel, J ;

Ohayon, J ;

Waidmann, TA ;

McFarland, HF ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) :8705-8708

[4]

DEPPER JM, 1984, J IMMUNOL, V133, P3054

[5] The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients [J].

Eckhoff, DE ;

McGuire, B ;

Sellers, M ;

Contreras, J ;

Frenette, L ;

Young, C ;

Hudson, S ;

Bynon, JS .

TRANSPLANTATION, 2000, 69 (09) :1867-1872

[6] Functional activities of the human T-cell leukemia virus type I Tax oncoprotein:: cellular signaling through NF-κB [J].

Jeang, KT .

CYTOKINE & GROWTH FACTOR REVIEWS, 2001, 12 (2-3) :207-217

[7]

JUNGHANS RP, 1990, CANCER RES, V50, P1495

[8] Phase I trial of recombinant immunotoxin anti-Tac(Fv)PE38 (LMB-2) in patients with hematologic malignancies [J].

Kreitman, RJ ;

Wilson, WH ;

White, JD ;

Stetler-Stevenson, M ;

Jaffe, ES ;

Giardina, S ;

Waldmann, TA ;

Pastan, I .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) :1622-1636

[9] Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis [J].

Krueger, JG ;

Walters, IB ;

Miyazawa, M ;

Gilleaudeau, P ;

Hakimi, J ;

Light, S ;

Sherr, A ;

Gottlieb, AB .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (03) :448-458

[10] Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac [J].

Lehky, TJ ;

Levin, MC ;

Kubota, R ;

Bamford, RN ;

Flerlage, AN ;

Soldan, SS ;

Leist, TP ;

Xavier, A ;

White, JD ;

Brown, M ;

Fleisher, TA ;

Top, LE ;

Light, S ;

McFarland, HF ;

Waldmann, TA ;

Jacobson, S .

ANNALS OF NEUROLOGY, 1998, 44 (06) :942-947

← 1 2 3 4 5 →